SubsidieMeestersLife Saving Technology for Thoracic Trauma Treatment and Post Operative Drainage
C-LANT is an innovative, multifunctional device designed to rapidly and effectively treat thoracic trauma, aiming to significantly reduce procedure time and healthcare costs while improving patient outcomes.
Projectdetails
Introduction
Thoracic trauma is the 1st cause of accidental death globally, with a mortality rate of 60% in polytraumatic patients. The time of treatment is crucial.
Importance of Timely Treatment
80% of patients can be potentially saved if they are treated within 1 hour. However, current solutions to treat thoracic trauma are limited and have remained static for the last 30-50 years.
C-LANT Device Overview
C-LANT is a unique self-fixating, a-traumatic, and multifunctional device that addresses this unmet need by offering:
- A safe and fast solution
- Easy to use functionality
- Multifunctional capabilities
- Cost-effective treatment for any type of chest trauma or postoperative drainage following major thoracic and abdominal procedures
Benefits of C-LANT
C-LANT significantly reduces procedure time by 20 times and saves up to €2.6 billion associated with additional tube replacement in the EU.
Future Plans with EIC Support
With the EIC support, Vigor aims to accelerate the clinical validation and scaling-up of C-LANT, providing a global impact on healthcare systems, clinicians, and patients.
Market Potential
C-LANT will be part of the growing Emergency Medical Devices and Surgical Drains markets, which are projected to be valued at over €40 billion by 2030.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.875 |
| Totale projectbegroting | € 3.571.250 |
Tijdlijn
| Startdatum | 1-3-2023 |
| Einddatum | 31-8-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- VIGOR MEDICAL TECHNOLOGIES LTDpenvoerder
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Minimally invasive suturing for vascular bore closure and heart defect repairNovelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Saving Cardiac Arrest Patients with Hypothermic Lung Conservative Liquid VentilationOrixha's LuncoLive project aims to clinically validate the Vent2Cool device for rapid cooling of cardiac arrest patients, enhancing survival rates while minimizing costs and environmental impact. | EIC Accelerator | € 2.449.869 | 2023 | Details |
Development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsyThe Selio System aims to prevent pneumothorax during lung biopsies by pre-sealing the needle tract, enhancing patient safety and reducing healthcare costs. | EIC Accelerator | € 2.499.999 | 2022 | Details |
Transformational crossing system to prevent amputation and treat complex chronic total occlusions in critical limb ischemiaVersono's CTO guidewire uses ultrasound to enable endovascular surgeons to effectively treat 90% of chronic total occlusions, aiming to restore blood flow and prevent limb amputation in CLTI patients. | EIC Accelerator | € 2.478.175 | 2023 | Details |
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry. | EIC Accelerator | € 2.497.469 | 2022 | Details |
Minimally invasive suturing for vascular bore closure and heart defect repair
Novelrad's NVCD closure device aims to minimize complications in large-bore vascular closures during cardiac surgeries through innovative micro-suturing technology, facilitating safer and faster procedures.
Saving Cardiac Arrest Patients with Hypothermic Lung Conservative Liquid Ventilation
Orixha's LuncoLive project aims to clinically validate the Vent2Cool device for rapid cooling of cardiac arrest patients, enhancing survival rates while minimizing costs and environmental impact.
Development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsy
The Selio System aims to prevent pneumothorax during lung biopsies by pre-sealing the needle tract, enhancing patient safety and reducing healthcare costs.
Transformational crossing system to prevent amputation and treat complex chronic total occlusions in critical limb ischemia
Versono's CTO guidewire uses ultrasound to enable endovascular surgeons to effectively treat 90% of chronic total occlusions, aiming to restore blood flow and prevent limb amputation in CLTI patients.
Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)
AMT Medical aims to revolutionize coronary artery disease treatment by developing a minimally invasive, cost-effective CABG surgery using innovative ELANA technology, seeking $7.5M for clinical validation and market entry.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
CLOBT: Cardiale Levensreddende Ondersteuning Booster TechnoCardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten. | Mkb-innovati... | € 155.376 | 2020 | Details |
Mediclose: Towards improved abdominal surgeryHet MIT R&D project ontwikkelt Mediclose, een automatisch chirurgisch instrument voor veilige sluiting van laparoscopische incisies, met als doel post-chirurgische complicaties te verminderen en kosten te verlagen. | Mkb-innovati... | € 315.490 | 2018 | Details |
XELENA Heart BypassXeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten. | Mkb-innovati... | € 318.850 | 2020 | Details |
MicroHeartHet project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie. | Mkb-innovati... | € 155.525 | 2018 | Details |
A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMAThis project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing. | EIC Pathfinder | € 2.792.500 | 2024 | Details |
CLOBT: Cardiale Levensreddende Ondersteuning Booster Techno
CardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten.
Mediclose: Towards improved abdominal surgery
Het MIT R&D project ontwikkelt Mediclose, een automatisch chirurgisch instrument voor veilige sluiting van laparoscopische incisies, met als doel post-chirurgische complicaties te verminderen en kosten te verlagen.
XELENA Heart Bypass
Xeltis en AMT Medical ontwikkelen een innovatieve bypass-technologie met regeneratieve kunstvaten en hechtingloze bevestiging, gericht op veiligere operaties en verbeterde patiëntresultaten.
MicroHeart
Het project ontwikkelt een gestandaardiseerd productieproces voor de ELANA Heart Bypass, een minimaal-invasieve behandeling voor coronaire hartziekten, ter verbetering van patiëntenzorg en commercialisatie.
A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA
This project aims to develop a novel cold atmospheric pressure plasma system for minimally invasive treatment of pancreatic and biliary tract cancers, integrating advanced modeling and in-vivo testing.